Answers are grounded in this paper and cite their sources.
Real-world insights reveal gaps in biomarker testing for mNSCLC, suggesting improvements in access and adherence to guidelines.
Most patients with mNSCLC did not undergo comprehensive biomarker testing, leading to potential missed opportunities for precision therapy. Disparities in testing and treatment underscore the need for expanded access to molecular diagnostics, payer support for comprehensive testing (including liquid biopsy), and alignment with national guidelines to improve outcomes and advance equitable cancer care.
No takes yet. Share an insight, caveat, or question.
Stanford et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: